Resultados en salud y eficiencia del fentanilo intranasal en pectina en el dolor irruptivo en la práctica clínica habitual

• Autores: Benjamín Blanco, Antonio José García Ruiz, Nuria García-Agua Soler
• Localización: Revista de la Sociedad Española del Dolor (SED), ISSN 1134-8046, Vol. 20, Nº. 5, 2013, págs. 221-229
• Idioma: español
• DOI: 10.4321/S1134-80462013000500004
• Títulos paralelos:
  • Health outcomes and efficiency of fentanyl pectin intranasal breakthrough cancer pain in clinical practice
• Enlaces
  • Texto completo (pdf)
• Resumen
  • español

    Objetivo: Conocer la efectividad y eficiencia del fentanilo intranasal en pectina comparado con otros tratamientos empleados en el dolor irruptivo oncológico a través de un análisis farmacoeconómico. Resultados y conclusiones: En la evaluación farmacoeconómica realizada, todas las opciones analizadas fueron coste-efectivas para una disposición a pagar (invertir) de 30.000 € por AVAC ganado (ratio coste/efectividad < 30.000 €). La opción más eficiente (mayor efectividad y menor coste) en todos los casos analizados es el espray intranasal de fentanilo en pectina (FPNS). En el análisis incremental, FPNS fue la opción dominante sobre todas las demás evaluadas: FST, OTFC, FBT e INFS. Del análisis de los datos de nuestro estudio de modelización de coste/efectividad del espray intranasal de fentanilo en pectina FPNS se concluye: - INFS sin proporcionar más eficacia ha demostrado ser significativamente más caro (+15 %). - FST, OTFC, FBT han demostrado una efectividad un 18 % menor que FPNS y además ser significativamente más caros (+9 %; +15 %; +10 %, respectivamente). Abreviaturas: AVAC: años ganados con buena calidad de vida. FPNS: PecFent®. FST: Abstral®. OTFC: Actiq®. FBT: Effentora®. INFS: Instanyl®.

  • English

    Objective: Determine, with a pharmacoeconomic evaluation, the effectiveness and efficiency of fentanyl pectin intranasal spray for BTPc versus other indicated treatments. Results and conclusions: All the treatments analyzed in the pharmacoeconomic evaluation were cost-effective in terms of a willingness to pay (invest) of € 30,000 per AVAC gained (cost / effectiveness ratio < € 30,000). The most efficient option (greater effectiveness and lower cost) of all the treatments analyzed was the fentanyl pectin nasal spray (FPNS). In the incremental analysis FPNS was the dominant treatment option over all the others evaluated: FST, OTFC, FBT and INFS. From the analysis of the data of our cost/effectiveness modeling study of the fentanyl pectin nasal spray, FPNS, we can conclude: - INFS without providing greater effectiveness has been shown to be significantly more expensive (+15 %). - FST, OTFC, FBT have demonstrated -18 % less effectiveness and also been shown to be significantly more expensive than FPNS (+9 %; +15 %; +10 %, respectively). Abbreviations: AVAC: Years gained with good quality of life. FPNS: PecFent®. FST: Abstral®. OTFC: Actiq®. FBT: Effentora®. INFS: Instanyl®.

• Referencias bibliográficas
  • Davies. (2009). The management of cancer-related breakthrough pain: Recommendations of a task group of the Science Committee of the Association...
  • Mercadante, S, Maddaloni, S, Roccella, S. (1992). Predictive factors in advance cancer pain treated only by analgesics. Pain. 50. 151
  • Faisinger. (2005). A multicenter study of the revised Edmonton Staging System for classifying cancer pain in advanced cancer patients. J Pain...
  • Portenoy, R.K.. (1999). Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 81. 129
  • Zeppetella, G. (2009). Impact and management of breakthrough pain in cancer. Curr Opin Support Palliat Care. 3. 1-6
  • Davies, A. (2013). Breakthrough Cancer Pain: An Observational Study of 1000 European Oncology Patients. J Pain Symptom Manage.
  • Zeppetella, G. (2013). Evidence-based treatment of cancer-related breakthrough pain with opioids. J Natl Compr Canc Netw. 11. 37-43
  • Vissers, D. (2010). Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer. Curr Med Res Opin. 26. 1037
  • Vissers, D, Nolte, T, Stam, WB. (2010). Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer. Curr Med...
  • Jensen, MP, Karoly, P, Braver, S. (1986). The measurement of clinical pain intensity: A comparison of six methods. Pain. 27. 1147
  • Downie, WW, Leatham, PA, Rhind, VM. (1978). Studies with pain rating scales. Ann Rheum Dis. 37. 378
  • Kremer, E, Atkinson, JH, Ignelzi, RJ. (1981). Measurement of pain: Patient preference does not confound pain measurement. Pain. 10. 241
  • Vissers, D, Lenre, M, Tolley, K, Jakobsson, J, Sendersky, V, Jansen, JP. (2011). An economic evaluation of short-acting opiods for treatment...
  • López-Bastida, J, Oliva, J, Antoñanzas, F, Garcia-Altes, A, Gisbert, R, Mar, J, Puig-Junoy, J. (2010). Spanish Recommendations on Economic...
  • Guidelines for the Economic Evaluation of Health Technologies.
  • ISPOR Good Outcomes Research Practices Index.
  • Sacristán, JA, Oliva, J, Del Llano, J. (2002). ¿Qué es una tecnología sanitaria eficiente en España?. Gac Sanit. 16. 334
  • García Ruiz, AJ, Morata García de la Puerta, F, Montesinos Gálvez, AC. (2008). Uso racional y eficiente del tratamiento hipocolesterolemiante....
  • Fortner, BV, Okon, TA, Portenoy, RK. (2002). A survey of pain-related hospitalizations, emergency department visits, and physician office...
  • Fortner, BV, Demarco, G, Irving, G, Ashley, J, Keppler, G, Chavez, J. (2003). Description and predictors of direct and indirect costs of pain...
  • Abernethy, AP, Wheeler, JL, Fortner, BV. (2008). A health economic model of breakthrough pain. American Journal of Managed Care. 14. 129
  • Burton, AW, Driver, LC, Mendoza, TR, Syed, G. (2004). Oral transmucosal fentanyl citrate in the outpatient management of severe cancer pain...
  • Taylor, DR, Webster, LR, Chun, SY. (2007). Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: Patient...